Close Menu

10X Genomics

 

10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.

 

10X Genomics Company Profile  

 

President & CEO: Serge Saxonov

CEO photo:

 10X Genomics CEO photo - Serge Saxonov

Website: http://10xgenomics.com

Headquarters: Pleasanton, CA

10x Genomics employees: 101-250

Funding: $113M USD

Founded: 2012

Founders: Serge Saxonov, Ben Hindson


 

10x Genomics News 

Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.

New cellular and molecular spatial biology methods, companies, and product offerings have made this area one of the hottest in the life science market.

For the three months ended Sept. 30, the company reported $71.8 million in revenues, up from $61.2 million in Q3 2019 and beating the average Wall Street estimate.

10x will develop a third genomics platform, possibly combining Cartana's more sensitive chemistry with ReadCoor's instrument.

The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.

The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.

The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.

The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.

The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.

Pages

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.